


*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**C-MER 希瑪**

**C-MER EYE CARE HOLDINGS LIMITED**

**希瑪眼科醫療控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 3309)**

**VOLUNTARY ANNOUNCEMENT**

**(1) ON-MARKET REPURCHASE OF SHARES**

**(2) SHARE PURCHASE PURSUANT TO  
THE 2022 SHARE AWARD SCHEME**

This announcement is made by C-MER Eye Care Holdings Limited (the “**Company**”) on a voluntary basis.

Reference is made to the announcement of the Company dated 7 September 2023 (the “**7 September 2023 Announcement**”) and also the 7 November 2022 Announcement. Unless otherwise defined, capitalised terms used in this announcement shall have the same meaning as used in the 7 September 2023 Announcement and the 7 November 2022 Announcement.

The Board wishes to announce that the Board has applied a total of HK\$10.4 million to (1) conduct on-market share repurchases of the Shares in the aggregate purchase amount of HK\$7.0 million under the Repurchase Mandate; and (2) paid to the Trust Contributed Amounts of HK\$3.4 million for the purchase of Shares in the market by the Trustee under the 2022 Share Award Scheme, for the five trading days ending on the date of this announcement.

**(1) ON-MARKET REPURCHASE OF SHARES**

The Board also wishes to announce that for the five trading days ending on the date of this announcement, the Company has repurchased on-market 1,904,000 Shares with an aggregate of HK\$7.0 million (before brokerage, stamp duties and other expenses) pursuant to the Repurchase Mandate. The highest price per Share repurchased was HK\$3.74, and the lowest price per Share repurchased was HK\$3.61. The Company will subsequently cancel the repurchased Shares.

## (2) SHARE PURCHASE PURSUANT TO THE 2022 SHARE AWARD SCHEME

The Board wishes to announce that for the five trading days ending on the date of this announcement, the Trustee has purchased a total of 908,000 Shares on-market. According to the terms of the Trust, unless otherwise determined by the Board, the Trustee shall hold these Shares for the benefit of the Selected Participants until they are vested, on and subject to the terms and conditions of the Scheme Rules and the Trust Deed.

Details of the Shares purchased and the latest information about the Shares held by the Trustee are as follows:

Purchase Period	:	11 and 12 September 2023
Total number of Shares purchased	:	908,000
Shares purchased as a percentage of the total existing number of Shares in issue as at the date of this announcement	:	0.072%
Average consideration per Share purchased	:	HK\$3.71
Balance of Shares held by the Trustee as at the date of this announcement	:	9,428,000

Subject to and in compliance with the requirements under the Listing Rules and the Scheme Rules, the Board may, from time to time, at its sole and absolute discretion select any Eligible Participant for participation in the 2022 Share Award Scheme as a Selected Participant and determine the number of Awarded Shares to be awarded to the respective Selected Participants, the terms and conditions before the Awarded Shares may be vested and other related matters as expressly provided under the Scheme Rules.

**Shareholders and prospective investors of the Company should note that any further Share repurchases and/or further purchases of Shares by the Trustee on-market will be subject to market conditions and will be at the absolute discretion of the Board. There is no assurance implied or given that as to the timing, quantity or prices of any further Share repurchases or purchases of Shares by the Trustee on-market, if at all. Shareholders and potential investors are therefore advised to exercise caution when dealing in the Shares.**

By order of the Board  
**C-MER Eye Care Holdings Limited**  
**Dr. LAM Shun Chiu Dennis**  
*Chairman and Chief Executive Officer and Executive Director*

Hong Kong, 15 September 2023

*As of the date of this announcement, the Board comprises three executive Directors, namely Dr. LAM Shun Chiu Dennis, Ms. LI Xiaoting and Dr. LEE Yau Wing Vincent; and four independent non-executive Directors, namely, Dr. Rex AU YEUNG Pak-kuen, Mr. MA Andrew Chiu Cheung, Mr. IP Shu Kwan Stephen and Mr. YIN Ke.*